Estrogen and progesterone receptor content of enucleated uterine myomata after luteinizing hormone-releasing hormone

Cirkel, U.; Ochs, H.; Roehl, Alexandra; Schneider, H. P. G.

doi:10.3109/01658109209058105

Cited by 4 publications

(8 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These ®ndings argue against the direct involvement of progesterone and gonadotrophin-releasing hormone agonist, and instead suggest that the in vivo effect is indirectly through gonadal suppression. Our results seem to collabourate with the ®ndings of Cirkel et al 25 . who reported that leiomyoma regression correlated to the oestrogen receptor content and independent of progesterone receptor.…”

Section: Dna Damage Caused By Oestrogen Deficiency 99supporting

confidence: 84%

Oestrogen deficiency causes DNA damage in uterine leiomyoma cells: a possible mechanism for shrinkage of fibroids by GnRH agonists

Cheng

Chou

Huang

et al. 2001

British Journal of Obstetrics and Gynaecology

View full text Add to dashboard Cite

Section: Dna Damage Caused By Oestrogen Deficiency 99supporting

confidence: 84%

Oestrogen deficiency causes DNA damage in uterine leiomyoma cells: a possible mechanism for shrinkage of fibroids by GnRH agonists

Cheng

Chou

Huang

et al. 2001

British Journal of Obstetrics and Gynaecology

View full text Add to dashboard Cite

“…These results suggest that the patterns of leiomyomata reduction may be the result of drug action on the cellular estrogen receptors. Vu et al (11) and Cirkel et al (12) have reported similar results when studying patients submitted to GnRH agonist treatment, independent of volume reduction, when compared to a control group. Cirkel et al (12) performed biopsies of the same leiomyoma node, bothbefore and after GnRH agonist treatment.…”

Section: Discussionmentioning

confidence: 64%

Effects of treatment with gonadotropin releasing hormone agonist on the uterine leiomyomata structure

Bozzini

Rodrigues

Petti

et al. 2003

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

show abstract

“…These results suggest that the patterns of leiomyomata reduction may be the result of drug action on the cellular estrogen receptors. Vu et al (11) and Cirkel et al (12) have reported similar results when studying patients submitted to GnRH agonist treatment, independent of volume reduction, when compared to a control group. Cirkel et al (12) per-formed biopsies of the same leiomyoma node, bothbefore and after GnRH agonist treatment.…”

Section: Discussionmentioning

confidence: 69%

“…Vu et al (11) and Cirkel et al (12) have reported similar results when studying patients submitted to GnRH agonist treatment, independent of volume reduction, when compared to a control group. Cirkel et al (12) per-formed biopsies of the same leiomyoma node, bothbefore and after GnRH agonist treatment. Their results support our findings, suggesting that the use of this drug could result in a decline in the percentage of ER+ cells.…”

Section: Discussionmentioning

confidence: 69%

“…Cirkel et al (12) also showed that the reduction of leiomyomata after GnRH agonist treatment was independent of the progesterone receptor concentration. Barbieri et al (13) administered progesterone to patients in order to reduce the side-effects of GnRH agonist treatment, and observed that patients who had received both drugs had a lower volume reduction than those who received GnRH agonist alone.…”

Section: Discussionmentioning

confidence: 96%

See 1 more Smart Citation

Effects of treatment with gonadotropin releasing hormone agonist on the uterine leiomyomata structure

Bozzini¹,

Rodrigues²,

Petti³

et al. 2003

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

Objective. Our aim was to study the effects of the gonadotropin releasing hormone agonist on the uterine leiomyoma of infertile women. Material and methods. Sixty-seven nulliparous women (aged 24-39 years) with uterine leiomyomas, underwent ultrasonographic study of leiomioma volume, and were divided in two groups. Thirty-one had nodes greater than 300 cm 3 and were treated with goserelin 3.6 mg every 28 days for 6 months (group I); the other 36 patients did not receive medication (group II or control group). Sixteen patients from group I had 436 (median) reduction of the leiomyoma volume (subgroup Ia) and the other 15 women had reduction >36 (subgroup Ib). All women underwent myomectomy.Results. The group with the greater leiomyoma reduction after treatment with goserelin (group Ib) showed a significantly lower percentage of ER+ when compared with group Ia and the control group. Group Ib had a significantly higher percentage of PR+ in relation to the control group, but not to group Ia. The number of blood vessels, AgNOR dots, and cells, and the amount of collagen were not different between the three groups studied. Leiomyomata reduction correlated negatively with the percentage ER+ cells, but positively with the PR+ cells, amount of collagen and number of blood vessels. No correlation was found between the number of AgNOR dots and cellularity. Conclusion. Our data strengthen the hypothesis that the uterine leiomyoma response to steroid hormones results from the presence of specific hormone receptors, and progesterone receptors may also play a role in the development of leiomyoma.

show abstract

Estrogen and progesterone receptor content of enucleated uterine myomata after luteinizing hormone-releasing hormone

Cited by 4 publications

References 22 publications

Oestrogen deficiency causes DNA damage in uterine leiomyoma cells: a possible mechanism for shrinkage of fibroids by GnRH agonists

Oestrogen deficiency causes DNA damage in uterine leiomyoma cells: a possible mechanism for shrinkage of fibroids by GnRH agonists

Effects of treatment with gonadotropin releasing hormone agonist on the uterine leiomyomata structure

Effects of treatment with gonadotropin releasing hormone agonist on the uterine leiomyomata structure

Contact Info

Product

Resources

About